Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 17/20 | 0.80 |
| ▸ | GBA1 | P04062 | 6/20 | 0.80 |
| ▸ | UGCG | Q16739 | 3/20 | 0.80 |
| ▸ | MGAM | O43451 | 2/20 | 0.80 |
| ▸ | SI | P14410 | 2/20 | 0.80 |
| ▸ | AGL | P35573 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23503370 | 1.00 | GAA (1.00) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL6820276 | 1.00 | GAA (1.00) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL6817340 | 1.00 | GAA (1.00) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL2772479 | 1.00 | GAA (1.00) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL14020271 | 1.00 | GAA (1.00) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL6135278 | 0.94 | GAA (0.89) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL6135413 | 0.94 | GAA (0.89) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL6135521 | 0.94 | GAA (0.89) | GAAGBA2GBA1UGCGMGAM | |
| Miglustat SCHEMBL20576705 | 0.89 | GBA2 (1.00) | GAAGBA2GBA1UGCGMGAM | |
| Miglustat SCHEMBL7911243 | 0.89 | GBA2 (1.00) | GAAGBA2GBA1UGCGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11033538-B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | AMICUS THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033538-B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | HSPA5, MAN2B1, GBA1 | GAA 5/4885GBA2 8/4885GBA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.